Biocryst Pharmaceuticals Inc 's (BCRX) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Biocryst Pharmaceuticals Inc   (NASDAQ: BCRX)
 



  Biocryst Pharmaceuticals Inc Outlook

On January 5 2024 the Biocryst Pharmaceuticals Inc provided following guidance

Biocryst Pharmaceuticals Inc. has recently revealed its preliminary full year 2023 net revenue for ORLADEYO (berotralstat) drug, amounting to $325 million. This figure reflects a notable 29 percent increase year-on-year.

In addition, the company has also provided guidance for the year 2024 and outlined an accelerated path towards profitability. With this announcement, Biocryst Pharmaceuticals Inc. aims to continue its positive trajectory and further strengthen its financial performance.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.